Phase 2 platform funding of £4.2 million is backing TOCSINS, a multicountry trial evaluating oral snakebite therapies, with Ophirex contracted to supply marimastat drug substance as one of the candidate interventions.
The core development is an academic–industry supply agreement: Ophirex will produce marimastat, a small‑molecule inhibitor of snake venom metalloproteinases, for the Liverpool School of Tropical Medicine’s Centre for Snakebite Research & Interventions. TOCSINS will run as a Phase 2 platform trial of novel oral treatments, an approach designed to cycle multiple agents through a common infrastructure and control arm. Sites are planned with partners at FMT‑HVD in Brazil and KCCR in Ghana, alongside collaborators from the University of Liverpool, Cambridge University, and Vrije Universiteit Amsterdam. The move situates marimastat alongside Ophirex’s lead program, varespladib, an oral sPLA2 inhibitor with U.S. regulatory designations, and reflects growing interest in dual‑target or sequential strategies that blunt the dominant toxin classes in many viperid envenomings.
Strategically, Ophirex’s role as manufacturer is an expansion play that keeps the company central to the emerging oral antivenom narrative without owning every trial. Providing GMP supply into an independent platform gives the firm line of sight into clinical signal generation for a complementary mechanism while preserving optionality around combinations with varespladib. It also externalizes part of the development risk to a grant‑funded consortium operating in high‑burden regions, while building credibility in rapid, field‑relevant manufacturing and distribution—capabilities that will be scrutinized if oral therapies move toward broad deployment. Preclinical work has suggested additive effects when metalloproteinase inhibition is paired with sPLA2 blockade; platform infrastructure is well suited to test that hypothesis in a controlled, antivenom‑containing standard‑of‑care environment.
For sites, TOCSINS brings a distinct operational profile. Enrollment will be acute and decentralized, often beginning in primary or district settings where most mortality occurs before hospital arrival. Oral dosing simplifies logistics relative to antivenom’s cold chain, infusion staffing, and anaphylaxis preparedness, but it raises executional demands around rapid triage, consent under time pressure, tight randomization windows, and near‑term endpoints such as bleeding control, coagulopathy normalization, tissue injury progression, need for rescue antivenom, and time to functional recovery. Supply chains must deliver shelf‑stable product to peripheral clinics, with clear algorithms to avoid delaying transfer for antivenom when indicated. CROs and data teams should expect pragmatic designs, adaptive arm management, and rigorous safety monitoring suited to short‑course rescue agents.
Regulators and policy bodies will focus on whether oral agents can demonstrably reduce antivenom utilization, shorten time to stabilization, or improve survival in defined species clusters, with particular attention to heterogeneity across viperid and elapid envenomings. Prior FDA designations for varespladib signal openness to novel modalities, but marimastat’s repurposing history—marked by musculoskeletal toxicity in chronic oncology settings—will put a premium on tolerability in brief dosing regimens. Convergence with WHO guidance, potential prequalification, and donor procurement pathways will hinge on consistency across geographies and operational feasibility at scale.
Key watch points are the TOCSINS protocol specifics, including initial arms, adaptive rules, and antivenom‑sparing endpoints; timing of first patient in at Brazilian and Ghanaian hubs; and whether a marimastat–varespladib combination advances after any single‑agent readouts. Early safety signals will determine dose intensity tolerability in acutely ill patients. The principal risks remain translational—animal model success may not generalize across venom ecologies—and operational, notably the hazard of prehospital use creating false reassurance that delays definitive care. If the platform can generate a clear, reproducible signal, the field will quickly pivot to questions of manufacturing scale, kit design for frontline distribution, and payer–donor frameworks to support broad access in low‑resource settings.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
